case_images: PMC8117341_01
case_images: Case 1 demonstrating (A) Increase in size of right thigh mass (B) CD3 positive (C) CD5 positive (D) CD 68 positive immunohistochemical staining.
case_images: fonc-11-679177-g001.jpg
case_images: PMC8117341_02_fonc-11-679177-g001.jpg
case_images: f1
case_images: Immunohistochemistry revealed CD4+ infiltrating lymphocytes and CD68+ histiocytes ( Figures 2C, D  and  Table 1 ).
case_images: PMC8117341_02
case_images: Case 1 demonstrating (A) Increase in size of right thigh mass (B) CD3 positive (C) CD5 positive (D) CD 68 positive immunohistochemical staining.
case_images: fonc-11-679177-g001.jpg
case_images: PMC8117341_02_fonc-11-679177-g001.jpg
case_images: f1
case_images: Immunohistochemistry revealed CD4+ infiltrating lymphocytes and CD68+ histiocytes ( Figures 2C, D  and  Table 1 ).
case_images: Case 2 demonstrating descending colon mass before (A) and after (B) nivolumab treatment; (C) CD4 positive (D) CD 68 positive immunohistochemical staining.
case_images: fonc-11-679177-g002.jpg
case_images: PMC8117341_02_fonc-11-679177-g002.jpg
case_images: f2
case_images: Follow up CT after 6 doses of nivolumab showed interval worsening of lung metastases, left hilar adenopathy, new liver and right adrenal metastases, and marked enlargement of the descending colon mass from 2.1 x 3.1 cm to 8.8 x 10.6 cm ( Figures 2A, B ). Immunohistochemistry revealed CD4+ infiltrating lymphocytes and CD68+ histiocytes ( Figures 2C, D  and  Table 1 ).
case_images: PMC8117341_03
case_images: Case 3 demonstrating stomach mass before (A) and after (B) nivolumab treatment (C) extensive necrosis with no viable tumor (H&E, x100).
case_images: fonc-11-679177-g003.jpg
case_images: PMC8117341_03_fonc-11-679177-g003.jpg
case_images: f3
case_images: There was also marked interval enlargement of a multilobular mass tethered to the gastric wall, from 1.3 x 1.5 cm to 5.0 x 7.0 cm, concerning for metastasis versus a second primary cancer ( Figures 3A, B ). However, biopsies revealed only extensive necrosis and inflammatory changes with focal granulation tissue response, and no evidence of viable malignancy ( Figure 3C ).